WC
GILD icon

Westerkirk Capital’s Gilead Sciences GILD Stock Holding History

Westerkirk Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
25,686
+20,500
+395% +$2.7M 0.31% 56
2026
Q1 		$723K Hold
5,186
– – 0.08% 123
2025
Q4 		$637K Sell
5,186
-425
-8% -$51.6K 0.06% 135
2025
Q3 		$623K Hold
5,611
– – 0.07% 177
2025
Q2 		$622K Buy
+5,611
New +$597K 0.08% 174

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Westerkirk Capital's GILD Position: Q2 2026 in Review

Westerkirk Capital increased its Gilead Sciences (GILD) stake by 395% in Q2 2026, buying an estimated $2.7M and bringing the position to 25,686 shares worth $3.25M. The position accounts for 0.31% of the portfolio, ranked #56.

Westerkirk Capital first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. 2,285 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Westerkirk Capital held 25,686 shares of Gilead Sciences worth $3.25M as of Q2 2026.
  • Westerkirk Capital bought 20,500 Gilead Sciences shares in Q2 2026, an estimated $2.7M.
  • Gilead Sciences made up 0.31% of Westerkirk Capital's portfolio in Q2 2026, its #56 holding.
  • Westerkirk Capital first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • 2,285 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Westerkirk Capital's 13F filing for Q2 2026, filed 10 Aug 2026.